Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) EBITDA (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed EBITDA for 12 consecutive years, with -$1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 34.43% year-over-year to -$1.2 million, compared with a TTM value of -$3.4 million through Sep 2025, down 352.66%, and an annual FY2024 reading of -$3.6 million, up 40.22% over the prior year.
  • EBITDA was -$1.2 million for Q3 2025 at Arcadia Biosciences, down from -$501000.0 in the prior quarter.
  • Across five years, EBITDA topped out at $2.1 million in Q1 2021 and bottomed at -$9.3 million in Q4 2021.
  • Average EBITDA over 5 years is -$2.0 million, with a median of -$1.8 million recorded in 2024.
  • Peak annual rise in EBITDA hit 134.6% in 2024, while the deepest fall reached 469.97% in 2024.
  • Year by year, EBITDA stood at -$9.3 million in 2021, then soared by 54.16% to -$4.2 million in 2022, then surged by 114.51% to $616000.0 in 2023, then crashed by 469.97% to -$2.3 million in 2024, then skyrocketed by 49.36% to -$1.2 million in 2025.
  • Business Quant data shows EBITDA for RKDA at -$1.2 million in Q3 2025, -$501000.0 in Q2 2025, and $530000.0 in Q1 2025.